Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Xeligekimab provides rapid symptom resolution across all clinical dimensions, high and sustained achievement of treatment targets, and comprehensive restoration of quality of life.
Anti-SARS-CoV-2 antibodies at baseline, more common with placebo, provided protection against poor clinical outcomes.
These findings on the pharmacology of VOS underscore the importance of rapidly restoring key protective functions of the microbiome in patients with recurrent CDI to achieve durable prevention of recurrence, as observed in the...
Ivarmacitinib provides rapid and continuous improvement across all anatomical regions in patients with moderate-to-severe AD.
Lobeglitazone as an add-on to empagliflozin and metformin significantly improved glycaemic control in patients with T2DM inadequately controlled on metformin and empagliflozin dual therapy.
RFX treatment reduced microbial richness and decreased the abundance of taxa typically enriched in advanced cirrhosis (e.g., Escherichia , Streptococcus , Veillonella ).
The patient-reported outcomes also improved sustainedly.
2.1%, p = 0.0421), rather than an increase in incidence (HR = 1.09, p = 0.2669).
Patients without radiographic progression through 2 years of secukinumab treatment had greater achievement of LDA states at week 104 than patients with radiographic progression.
Upadacitinib effectively reduced pain in active RA and PsA, including in patients with AoI.
In a low-mortality setting, there was not clear evidence that neonatal BCG vaccination significantly reduces the incidence of early life hospitalisation for LRTI, infections or breathing illness.
MRNA-1283.815 elicited noninferior neutralizing antibody responses to mRNA-1273.815 against Omicron XBB.1.5 at Day 29, meeting the primary immunogenicity objective, with the GMR indicating higher responses of mRNA-1283.815 vs...
These results validate JSpADA as a disease activity measure for children with ERA and jPsA in a prospective clinical trial setting.
In addition to a significant and sustained day and night-time ambulatory BP reduction, aprocitentan was associated with a higher proportion of patients experiencing dipping pattern normalization and more pronounced BP load...
CONCLUSION: Our extensive pharmacogenomic/PK/safety analysis in patients with AML does not indicate the need for dose adjustments of midostaurin based on CYP3A4/CYP3A5 polymorphic variants.
ATSB Sarabi v.1.2 as deployed in western Zambia were not likely to be cost -effective.
This novel truncated protein, previously unreported in the literature, is associated with the disruption of the Wnt pathway and T-cell receptor signaling, which can be exploited as a therapeutic strategy to enhance...
Tolvaptan was associated with large increases in free water clearance and urine output.
WWI is closely associated with future heart and blood vessel outcomes and TM in patients with T2DM.WWI serves as an autonomous predictor of both future heart and blood vessel events and TM among patients with T2DM,...
We present and propose the use of a pharmacometric-based body composition model to describe weight reduction in future clinical trials investigating similar drugs in similar patient populations, in lieu of DXA scans.
In a pooled analysis, slow heart rate was observed in 6% of terlipressin-treated patients but rarely required a dose interruption or reduction.
The onset of action for fezolinetant was observed from day 1 for VMS frequency and severity and was maintained for 52 weeks.
Carotegrast methyl appears most effective in patients with moderately active ulcerative colitis with low disease activity, with week 2 and beyond as an appropriate time point for assessing efficacy.
This study supports the use of MenACYW-TT in infants aged 6 weeks (42 days) or older.
A low-dose prednisone plus methotrexate regimen is non-inferior to standard-dose prednisone in achieving full symptom relief in idiopathic retroperitoneal fibrosis, allowing significant reduction in glucocorticoid exposure.
Early itch relief with ivarmacitinib showed significant improvements in QoL, sleep, and work productivity in patients with moderate-to-severe AD.
Reduced elective dose resulted in significantly more patients with a pharyngeal mucosal epithelium mean dose below 45 Gy.
Moreover, the magnitude of the immune response was similar to the antibody levels detected in sera from convalescent chikungunya patients.
Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations.
An analysis of HAI titers as a correlate of protection against influenza infection provided support for its use as a.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
